CA2413435A1 - A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists - Google Patents
A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists Download PDFInfo
- Publication number
- CA2413435A1 CA2413435A1 CA002413435A CA2413435A CA2413435A1 CA 2413435 A1 CA2413435 A1 CA 2413435A1 CA 002413435 A CA002413435 A CA 002413435A CA 2413435 A CA2413435 A CA 2413435A CA 2413435 A1 CA2413435 A1 CA 2413435A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor
- amino acid
- sequence
- human
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 26
- 239000005557 antagonist Substances 0.000 title claims abstract description 18
- 238000012216 screening Methods 0.000 title claims abstract description 12
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 title abstract description 6
- 108010021336 lanreotide Proteins 0.000 title abstract description 6
- 229960002437 lanreotide Drugs 0.000 title abstract description 6
- 102000005962 receptors Human genes 0.000 claims abstract description 71
- 108020003175 receptors Proteins 0.000 claims abstract description 71
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 36
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000036623 Severe mental retardation Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 206010046555 Urinary retention Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 238000004166 bioassay Methods 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000008636 Neoplastic Processes Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000012292 cell migration Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000002816 gill Anatomy 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 abstract description 9
- 238000009826 distribution Methods 0.000 abstract description 5
- 108010000239 Aequorin Proteins 0.000 abstract description 4
- 239000003446 ligand Substances 0.000 abstract description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract description 4
- 101100238508 Rattus norvegicus Mrgprf gene Proteins 0.000 abstract description 3
- 210000001550 testis Anatomy 0.000 abstract description 3
- 210000001541 thymus gland Anatomy 0.000 abstract description 3
- 210000004291 uterus Anatomy 0.000 abstract description 3
- 238000012512 characterization method Methods 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 6
- 102000030782 GTP binding Human genes 0.000 description 6
- 108091000058 GTP-Binding Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 4
- -1 inositol phosphates Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 description 2
- 101000603411 Homo sapiens Neuropeptides B/W receptor type 2 Proteins 0.000 description 2
- 101000644251 Homo sapiens Urotensin-2 receptor Proteins 0.000 description 2
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038843 Neuropeptides B/W receptor type 2 Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100020942 Urotensin-2 receptor Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010041089 apoaequorin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 102000049143 human ID1 Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- DQRZBOYXYFUFGA-UHFFFAOYSA-N 7-benzyl-4-[(4-hydroxyphenyl)methyl]-2,5,8-triazatetracyclo[7.7.0.02,6.010,15]hexadeca-1(9),3,5,7,10(15),11,13-heptaene-3,13-diol Chemical compound Oc1c(Cc2ccc(O)cc2)nc2c(Cc3ccccc3)nc3-c4ccc(O)cc4Cc3n12 DQRZBOYXYFUFGA-UHFFFAOYSA-N 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 1
- 108700020473 Cyclic AMP Receptor Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091008881 GPCRs class D Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101001016827 Homo sapiens Histamine H2 receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 101500025319 Mus musculus Galanin Proteins 0.000 description 1
- 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000015925 Proto-oncogene Mas Human genes 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100283688 Rattus norvegicus Gpr26 gene Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 229940127593 SEQ-9 Drugs 0.000 description 1
- 101150006985 STE2 gene Proteins 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000052301 human GNAZ Human genes 0.000 description 1
- 102000044989 human HCAR3 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003572 second messenger assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
Abstract
The present invention is related to a G-protein coupled receptor or GPCRx11 similar to rat RTA receptor (37 %) and expressed in testis, thymus and uterus.
Aequorin cell line expressing GPCRx11 has been used for screening of tissue extracts and reference ligands. GPCRx11 cells gave a specific signal with synthetic angiopeptin and a somatostatin analog allowing to validate this cell line for screening of natural or synthetic agonists and antagonists. In parallel, extended tissue distribution and polyclonal antibodies have been produced to facilitate GPCRx11 characterisation.
Aequorin cell line expressing GPCRx11 has been used for screening of tissue extracts and reference ligands. GPCRx11 cells gave a specific signal with synthetic angiopeptin and a somatostatin analog allowing to validate this cell line for screening of natural or synthetic agonists and antagonists. In parallel, extended tissue distribution and polyclonal antibodies have been produced to facilitate GPCRx11 characterisation.
Description
A RECOMBINANT CELL LINE EXPRESSING GPCRxll AS A FUNCTIONAL
RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING
OF AGONISTS AND ANTAGONISTS
Field of the invention [0001] The present invention is related to a newly identified member of the superfamily of G-protein-coupled receptors as well as to the various uses that can be made of said receptor.
[00027 The invention is also related to the polynucleic acid sequence (polynucleotide) encoding said receptor.
[0003] The invention is further related to methods using receptor polypeptide and polynucleotide applicable to diagnostic and treatment in receptor-mediated disorders.
[0004] The invention is further related to drug-screening methods using the receptor polypeptide and polynucleotide, to identify agonists and antagonists applicable to diagnostic, prevention and/or treatment of said various disorders.
[0005] The invention further encompasses unknown agonists and antagonists detected and recovered based on the receptor polypeptide and polynucleotide.
[0006] The invention is further related to procedures for producing the receptor polypeptide and polynucleotide according to the invention, preferably by genetic recombinant methods.
RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING
OF AGONISTS AND ANTAGONISTS
Field of the invention [0001] The present invention is related to a newly identified member of the superfamily of G-protein-coupled receptors as well as to the various uses that can be made of said receptor.
[00027 The invention is also related to the polynucleic acid sequence (polynucleotide) encoding said receptor.
[0003] The invention is further related to methods using receptor polypeptide and polynucleotide applicable to diagnostic and treatment in receptor-mediated disorders.
[0004] The invention is further related to drug-screening methods using the receptor polypeptide and polynucleotide, to identify agonists and antagonists applicable to diagnostic, prevention and/or treatment of said various disorders.
[0005] The invention further encompasses unknown agonists and antagonists detected and recovered based on the receptor polypeptide and polynucleotide.
[0006] The invention is further related to procedures for producing the receptor polypeptide and polynucleotide according to the invention, preferably by genetic recombinant methods.
Background of the invention [0007] G-protein coupled receptors (GPCRs) are proteins responsible for transducing a signal within a cell. GPCRs have usually seven transmembrane domains. Upon binding of a ligand to an extra-cellular portion or fragment of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property or behaviour of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signalling system that connects the state of intra-cellular second messengers to extra-cellular inputs.
[0008] GPCR genes and gene products are potential causative agents of disease and these receptors seem to be of critical importance to both the central nervous system and peripheral physiological processes.
[0009] The GPCR protein superfamily is represented in five families . Family I, receptors typified by rhodopsin and the beta2-adrenergic receptor and currently represented by over 200 unique members; Family II, the parathyroid hormone/calcitoninjsecretin receptor family;
Family III, the metabotropic glutamate receptor family, Family IV, the CAMP receptor family, important in the chemotaxis and development of D. discoideum; and Family V, the fungal mating pheromone receptor such as STE2.
[0010] G proteins represent a family of heterotrimeric proteins composed of a, (3 and y subunits, that bind guanine nucleotides. These proteins are usually linked to cell surface receptors (receptors containing seven transmembrane domains).
[0011] Following ligand binding to~ the GPCR, a conformational change is transmitted to the G protein, which caused the a-subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the (3y-subunits.
[0012] The GTP-bound form of the a, (3 and y-subunits typically functions as an effector-modulating moiety, leading to the production of second messengers, such as CAMP (e. g. by activation of adenyl cyclase), diacylglycerol or inositol phosphates.
[0013] Greater than 20 different types of a-subunits are known in humans. These subunits associate with a small pool of (3 and y subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish et al., Molecular Cell Biology,(Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference.
[0014] Known and unknown GPCRs constitute now major targets for drug action and development.
[0015] Therefore, it exists a need for providing new G protein coupled receptors which could be used for the screening of new agonists and antagonists having advantageous potential prophylactic and therapeutical properties.
[0016] More than 300 GPCRs have been cloned thus far and it is generally assumed that it exists well over 1000 such receptors. Mechanistically, approximately 50-600 of all clinically relevant drugs act by modulating the functions of various GPCRs (Cudermann et al., J. Mol. Med., Vol. 73, pages 51-63, 1995).
[0008] GPCR genes and gene products are potential causative agents of disease and these receptors seem to be of critical importance to both the central nervous system and peripheral physiological processes.
[0009] The GPCR protein superfamily is represented in five families . Family I, receptors typified by rhodopsin and the beta2-adrenergic receptor and currently represented by over 200 unique members; Family II, the parathyroid hormone/calcitoninjsecretin receptor family;
Family III, the metabotropic glutamate receptor family, Family IV, the CAMP receptor family, important in the chemotaxis and development of D. discoideum; and Family V, the fungal mating pheromone receptor such as STE2.
[0010] G proteins represent a family of heterotrimeric proteins composed of a, (3 and y subunits, that bind guanine nucleotides. These proteins are usually linked to cell surface receptors (receptors containing seven transmembrane domains).
[0011] Following ligand binding to~ the GPCR, a conformational change is transmitted to the G protein, which caused the a-subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the (3y-subunits.
[0012] The GTP-bound form of the a, (3 and y-subunits typically functions as an effector-modulating moiety, leading to the production of second messengers, such as CAMP (e. g. by activation of adenyl cyclase), diacylglycerol or inositol phosphates.
[0013] Greater than 20 different types of a-subunits are known in humans. These subunits associate with a small pool of (3 and y subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish et al., Molecular Cell Biology,(Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference.
[0014] Known and unknown GPCRs constitute now major targets for drug action and development.
[0015] Therefore, it exists a need for providing new G protein coupled receptors which could be used for the screening of new agonists and antagonists having advantageous potential prophylactic and therapeutical properties.
[0016] More than 300 GPCRs have been cloned thus far and it is generally assumed that it exists well over 1000 such receptors. Mechanistically, approximately 50-600 of all clinically relevant drugs act by modulating the functions of various GPCRs (Cudermann et al., J. Mol. Med., Vol. 73, pages 51-63, 1995).
Summary of the invention [0017] The present invention is related to newly identified member of G-protein-coupled receptor, preferably a human receptor, as well as to the polynucleotide sequence encoding said human receptor described hereafter (SEQ ID
NO. 1 and 2).
[00l8] The present invention is also related to other newly identified members of G-protein-coupled receptors, preferably human receptors, as well as to the polynucleotide sequence encoding said other human receptor described hereafter (SEQ ID NO. 3 to SEQ ID NO. 22).
[00l9] The present invention is also related to nucleotidic and/or amino acid sequence homologous to the sequences corresponding to the receptor described hereafter.
[0020] An homologous sequence (which may exist in other mammal species) means a sequence which presents a high sequence identity or homology (which presents an identity higher than 70 0, 75°s, 80 0, 85%, 90 o or 95%) with the complete human sequence described hereafter, and preferably characterised by a similar pharmacology, especially a preference for binding angiopeptin and/or somatostatin analogs.
[0021] Another aspect of the present invention is related to a specific active portion of said sequence. Said active portion could be a receptor which comprises a partial deletion upon the complete nucleotide or amino acid sequence and which still maintains the active sites) necessary for the binding of specific ligands able to interact with said receptor.
[0022] Homologous sequences of the sequence according to the invention may comprise similar receptors which exist in other animal (rat, mouse, dog, etc.) or specific human populations, but which are involved in the same biochemical pathway.
[0023] Such homologous sequences may comprise addition, deletion or substitution of one or more amino 5 acids or nucleotides, which does not substantially alter the functional characteristics of the receptor according to the invention.
[0024] Thus, the invention encompasses also a receptor and corresponding nucleotide sequence having exactly the same amino acid or nucleotide sequences as shown in the enclosed sequence listing, as well as molecules which differ, but which are retaining the basic qualitative binding properties of the complete receptor according to the invention.
[0025] The invention is preferably related to said (human) receptor characterised by the complete nucleotide and amino acid sequences described hereafter, to unknown (and not previously described in the state of the art) agonist, reverse agonist and antagonist compounds or inhibitors of said receptor. Preferably, said inhibitors are antisens RNAs, rybo~ymes or antibodies (or specific hypervariable (FAB, FAB'2, ...) portions thereof) that bind specifically to said receptor or its encoding nucleotide sequence (i.e. that have at least a 10 fold greater affinity for said receptors than any other naturally occurring antibody). Said specific antibodies are preferably obtained by a process involving the injection of a pharmaceutically acceptable preparation of suoh amino acid sequence into a animal capable of producing antibodies directed against said receptor.
[0026] For instance, a monoclonal antibody directed to the receptor according to the invention is obtained by injecting of an expression plasmid comprising the DNA
NO. 1 and 2).
[00l8] The present invention is also related to other newly identified members of G-protein-coupled receptors, preferably human receptors, as well as to the polynucleotide sequence encoding said other human receptor described hereafter (SEQ ID NO. 3 to SEQ ID NO. 22).
[00l9] The present invention is also related to nucleotidic and/or amino acid sequence homologous to the sequences corresponding to the receptor described hereafter.
[0020] An homologous sequence (which may exist in other mammal species) means a sequence which presents a high sequence identity or homology (which presents an identity higher than 70 0, 75°s, 80 0, 85%, 90 o or 95%) with the complete human sequence described hereafter, and preferably characterised by a similar pharmacology, especially a preference for binding angiopeptin and/or somatostatin analogs.
[0021] Another aspect of the present invention is related to a specific active portion of said sequence. Said active portion could be a receptor which comprises a partial deletion upon the complete nucleotide or amino acid sequence and which still maintains the active sites) necessary for the binding of specific ligands able to interact with said receptor.
[0022] Homologous sequences of the sequence according to the invention may comprise similar receptors which exist in other animal (rat, mouse, dog, etc.) or specific human populations, but which are involved in the same biochemical pathway.
[0023] Such homologous sequences may comprise addition, deletion or substitution of one or more amino 5 acids or nucleotides, which does not substantially alter the functional characteristics of the receptor according to the invention.
[0024] Thus, the invention encompasses also a receptor and corresponding nucleotide sequence having exactly the same amino acid or nucleotide sequences as shown in the enclosed sequence listing, as well as molecules which differ, but which are retaining the basic qualitative binding properties of the complete receptor according to the invention.
[0025] The invention is preferably related to said (human) receptor characterised by the complete nucleotide and amino acid sequences described hereafter, to unknown (and not previously described in the state of the art) agonist, reverse agonist and antagonist compounds or inhibitors of said receptor. Preferably, said inhibitors are antisens RNAs, rybo~ymes or antibodies (or specific hypervariable (FAB, FAB'2, ...) portions thereof) that bind specifically to said receptor or its encoding nucleotide sequence (i.e. that have at least a 10 fold greater affinity for said receptors than any other naturally occurring antibody). Said specific antibodies are preferably obtained by a process involving the injection of a pharmaceutically acceptable preparation of suoh amino acid sequence into a animal capable of producing antibodies directed against said receptor.
[0026] For instance, a monoclonal antibody directed to the receptor according to the invention is obtained by injecting of an expression plasmid comprising the DNA
encoding said receptor into a mouse and than fusing mouse spleen cells with myeloma cells.
[0027] The present invention is also related to the polynucleotide according to the invention, possibly linked to other expression sequences and incorporated into a vector (plasmids, viruses, liposomes, cationic vesicles,...) and host cells transformed by such vector.
[0028] The present invention is also related to the recombinant, preferably human receptor according to the invention, produced by such host cells according to the method well known by the person skilled in the art, as well as a functional assay (diagnostic kit) comprising all the means and media for the identification of the receptor, its nucleotide sequence, as well as agonist, reverse agonist, antagonist and inhibitor of said receptor or its nucleotide sequence. Said diagnostic kit comprises preferably the following elements . the receptor, its encoding nucleotide sequence, antibodies directed against said receptor or its nucleotide sequence, as well as possible agonist, reverse agonist, antagonist or inhibitor compounds of said receptor. Said diagnostic kit comprises means and media for performing said diagnostic preferably through a measure of dosage/activity of said receptor, by genetic analysis of the receptor nucleotide sequence, preferably by RT/PCR or by immuno-analysis, preferably by the use of antibodies directed against said receptor.
[0029] The present invention is also related to a transgenic non-human mammal comprising a partial or total deletion of the genetic sequence encoding the receptor according to the invention, preferably a non human mammal comprising an homologous recombination "knock-out" of the nucleotide sequence (polynucleotide) according to the invention or a transgenic non human mammal overexpressing above natural level said polynucleotide sequence.
[0027] The present invention is also related to the polynucleotide according to the invention, possibly linked to other expression sequences and incorporated into a vector (plasmids, viruses, liposomes, cationic vesicles,...) and host cells transformed by such vector.
[0028] The present invention is also related to the recombinant, preferably human receptor according to the invention, produced by such host cells according to the method well known by the person skilled in the art, as well as a functional assay (diagnostic kit) comprising all the means and media for the identification of the receptor, its nucleotide sequence, as well as agonist, reverse agonist, antagonist and inhibitor of said receptor or its nucleotide sequence. Said diagnostic kit comprises preferably the following elements . the receptor, its encoding nucleotide sequence, antibodies directed against said receptor or its nucleotide sequence, as well as possible agonist, reverse agonist, antagonist or inhibitor compounds of said receptor. Said diagnostic kit comprises means and media for performing said diagnostic preferably through a measure of dosage/activity of said receptor, by genetic analysis of the receptor nucleotide sequence, preferably by RT/PCR or by immuno-analysis, preferably by the use of antibodies directed against said receptor.
[0029] The present invention is also related to a transgenic non-human mammal comprising a partial or total deletion of the genetic sequence encoding the receptor according to the invention, preferably a non human mammal comprising an homologous recombination "knock-out" of the nucleotide sequence (polynucleotide) according to the invention or a transgenic non human mammal overexpressing above natural level said polynucleotide sequence.
[0030] Said transgenic non-human mammal can be obtained by methods well known by the person skilled in the art, for instance by the one described in the document W098/20112 using classical techniques based upon the transfection of embryonic stem cells, preferably according to the method described by Carmeliet et al., Nature, Vol. 380, p. 435-439, 1996.
[0031] Preferably, in said transgenic non human mammal overexpressing, the polynucleotide according to the invention or active portions thereof has been previously incorporated in a DNA construct with an inducible promoter allowing its overexpression and possibly with tissues and other specific regulatory elements.
[0032] Another aspect of the present invention is related to a method and kit for performing said method for the screening (detection and possibly recovering) of compounds or a natural extract which are unknown (not yet described in the state of the art) or not known to be agonists, reverse agonists, antagonists or inhibitors of natural compounds to the receptor according to the invention, said method comprising .
- contacting a cell or cell extract from the cell transfected with a vector expressing the polynucleotide encoding the receptor according to the invention or active portions) thereof, - possibly isolating a membrane fraction from the cell extract or the complete cell with a compound or molecules present in said natural extract under conditions permitting binding of said compound or said mixture of molecules to said receptor, possibly by the activation of a functional response and - detecting the presence (and possibly the binding) of said compound or said mixture of molecules to said receptor by means of a bioassay, (preferably a modification in the production of a second messenger or an increase in the receptor activity) in the presence of another compound working as an agonist, reverse agonist, antagonist or inhibitor to the receptor according to the invention and thereby possibly recovering and determining whether said compound or mixture of molecules is (are) able to work as agonist, reverse agonist, antagonist, or inhibitor of the compound to its receptor.
[0033] Preferably, the second messenger assay comprises the measurement of intra-cellular cAMP, intracellular inositol phosphates, intra-cellular diacylglycerol concentrations, arachinoid acid concentration, MAP kinase(s) or tyrosine kinase(s) pathways activation or intra-cellular calcium mobilisation.
[0034] Preferably, said bioassay is validated by the addition of angiopeptin and any other suitable related peptides to the receptor according to the invention by a method well-known by the person skilled in the art and described hereafter.
[0035] The screening method according to the invention could be performed by well known methods to the person skilled in the art, preferably by high-throughput screening, diagnostic and dosage devices based upon the method described in the International patent application WO00/02045 performed upon various solid supports such as micro-titer plates or biochips (microarrays) according to known techniques by the person skilled in the art.
[0036] The present invention is also related .to the known or unknown compound or molecules characterised and possibly recovered by said method for its (their) use as a medicament in therapy and is related to the pharmaceutical composition comprising a sufficient amount of said compound or molecules) and a pharmaceutically acceptable carrier or diluent for the preparation of a medicament in the prevention and/or the treatment of various diseases.
[0037] In the pharmaceutical composition, the carrier or the adequate pharmaceutical carrier or diluant can be any solid, liquid or gaseous support which is non toxic and adapted for the administration (in vivo or ex vivo) to the patient, including the human, through various administration roots such as oral administration, intravenous administration, intradermal administration, etc.
[0038] Said pharmaceutical composition may comprise also various vesicles or adjuvants well known by the person skilled in the art, able to modulate the immune response of the patient. The percentage of active compound-molecules/
pharmaceutical carriers can vary, the range being only limited by the tolerance and the efficiency of the- active compounds to the patient. Said ranges of administration are also limited by the frequency of administration and the possible side effects of the compound or molecules.
[0039] A further aspect of the present invention is related to said unknown compound or molecules) identified by said screening method, to the pharmaceutical composition comprising it and to their use in the treatment of viral infections or diseases induced by various viruses or bacteria, the treatment or prevention of disturbances of cell migration, diseases or perturbations of the immune system, including cancer, development of tumours and tumour metastasis, inflammatory and neo-plastic processes, bacterial and fungal infections, for wound and bone healing and dysfunction of regulatory growth functions, pains, diabetes, obesity, anorexia, bulimia, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, restenosis, atherosclerosis, diseases characterised by excessive smooth muscle cell proliferation, aneurysms, wound healing, diseases characterised by loss of smooth muscle cells or reduced smooth muscle cell proliferation, stroke, ischemia, ulcers, allergies, benign prostatic hypertrophy, migraine, 5 vomiting, psychotic arid neurological disorders, including anxiety, schizophrenia, maniac depression, depression, delirium, dementia and severe mental retardation, degenerative diseases, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, and 10 dyskinasias, such as Huntington's disease or Gilles de la Tourett's syndrome and other related diseases.
[0040] Among the mentioned diseases the preferred applications are related to therapeutic agents targeting 7TM receptor that can play a function in preventing, improving or correcting dysfunctions or diseases, including, but not limited to fertility, fetal development, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV1 and HIV2, pain, cancer, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, psychotic and neurological disorders including anxiety, depression, migraine, vomiting, stroke, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome.
[0041] This invention relates to the use of a human G protein-coupled receptor as a screening tool to identify agonists or antagonists of the aequorin luminescence resulting from expression of this receptor.
[0031] Preferably, in said transgenic non human mammal overexpressing, the polynucleotide according to the invention or active portions thereof has been previously incorporated in a DNA construct with an inducible promoter allowing its overexpression and possibly with tissues and other specific regulatory elements.
[0032] Another aspect of the present invention is related to a method and kit for performing said method for the screening (detection and possibly recovering) of compounds or a natural extract which are unknown (not yet described in the state of the art) or not known to be agonists, reverse agonists, antagonists or inhibitors of natural compounds to the receptor according to the invention, said method comprising .
- contacting a cell or cell extract from the cell transfected with a vector expressing the polynucleotide encoding the receptor according to the invention or active portions) thereof, - possibly isolating a membrane fraction from the cell extract or the complete cell with a compound or molecules present in said natural extract under conditions permitting binding of said compound or said mixture of molecules to said receptor, possibly by the activation of a functional response and - detecting the presence (and possibly the binding) of said compound or said mixture of molecules to said receptor by means of a bioassay, (preferably a modification in the production of a second messenger or an increase in the receptor activity) in the presence of another compound working as an agonist, reverse agonist, antagonist or inhibitor to the receptor according to the invention and thereby possibly recovering and determining whether said compound or mixture of molecules is (are) able to work as agonist, reverse agonist, antagonist, or inhibitor of the compound to its receptor.
[0033] Preferably, the second messenger assay comprises the measurement of intra-cellular cAMP, intracellular inositol phosphates, intra-cellular diacylglycerol concentrations, arachinoid acid concentration, MAP kinase(s) or tyrosine kinase(s) pathways activation or intra-cellular calcium mobilisation.
[0034] Preferably, said bioassay is validated by the addition of angiopeptin and any other suitable related peptides to the receptor according to the invention by a method well-known by the person skilled in the art and described hereafter.
[0035] The screening method according to the invention could be performed by well known methods to the person skilled in the art, preferably by high-throughput screening, diagnostic and dosage devices based upon the method described in the International patent application WO00/02045 performed upon various solid supports such as micro-titer plates or biochips (microarrays) according to known techniques by the person skilled in the art.
[0036] The present invention is also related .to the known or unknown compound or molecules characterised and possibly recovered by said method for its (their) use as a medicament in therapy and is related to the pharmaceutical composition comprising a sufficient amount of said compound or molecules) and a pharmaceutically acceptable carrier or diluent for the preparation of a medicament in the prevention and/or the treatment of various diseases.
[0037] In the pharmaceutical composition, the carrier or the adequate pharmaceutical carrier or diluant can be any solid, liquid or gaseous support which is non toxic and adapted for the administration (in vivo or ex vivo) to the patient, including the human, through various administration roots such as oral administration, intravenous administration, intradermal administration, etc.
[0038] Said pharmaceutical composition may comprise also various vesicles or adjuvants well known by the person skilled in the art, able to modulate the immune response of the patient. The percentage of active compound-molecules/
pharmaceutical carriers can vary, the range being only limited by the tolerance and the efficiency of the- active compounds to the patient. Said ranges of administration are also limited by the frequency of administration and the possible side effects of the compound or molecules.
[0039] A further aspect of the present invention is related to said unknown compound or molecules) identified by said screening method, to the pharmaceutical composition comprising it and to their use in the treatment of viral infections or diseases induced by various viruses or bacteria, the treatment or prevention of disturbances of cell migration, diseases or perturbations of the immune system, including cancer, development of tumours and tumour metastasis, inflammatory and neo-plastic processes, bacterial and fungal infections, for wound and bone healing and dysfunction of regulatory growth functions, pains, diabetes, obesity, anorexia, bulimia, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, restenosis, atherosclerosis, diseases characterised by excessive smooth muscle cell proliferation, aneurysms, wound healing, diseases characterised by loss of smooth muscle cells or reduced smooth muscle cell proliferation, stroke, ischemia, ulcers, allergies, benign prostatic hypertrophy, migraine, 5 vomiting, psychotic arid neurological disorders, including anxiety, schizophrenia, maniac depression, depression, delirium, dementia and severe mental retardation, degenerative diseases, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, and 10 dyskinasias, such as Huntington's disease or Gilles de la Tourett's syndrome and other related diseases.
[0040] Among the mentioned diseases the preferred applications are related to therapeutic agents targeting 7TM receptor that can play a function in preventing, improving or correcting dysfunctions or diseases, including, but not limited to fertility, fetal development, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV1 and HIV2, pain, cancer, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, psychotic and neurological disorders including anxiety, depression, migraine, vomiting, stroke, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome.
[0041] This invention relates to the use of a human G protein-coupled receptor as a screening tool to identify agonists or antagonists of the aequorin luminescence resulting from expression of this receptor.
Example l: Cloning of human GPCRxII receptor [0042] In order to identify and clone novel human GPCR
(G-protein coupled receptor) the following approach was used. Sequences of the following GPCR: GPR8, ChemR23, HM74 and GPR14 were used as queries to search for homologies in public high-throughput genomic sequence databases (NCBI).
[0043] Using the above strategies, a novel human sequence of GPCR was identified. We called this new GPCR:
GPCRxll (SEQ ID number 1 and 2).
[0044] Tn order to clone the GPCRxII sequence we performed a polymerase chain reaction (PCR) on total human genomic DNA. Primers were synthetized based upon the GPCRxll human sequence and were as follows:
SEQ ID 23 GPCRxII fw: 5'-ccggaattcaccatggatccaaccaccccg-3' SEQ ID 24 GPCRxII rv: 5'-ctagtctagactctacaccagactgcttctc-3' [0045] Amplification resulted in a fragments of 0.99 kilobase containing the entire coding sequence of the GPCRxIl gene. This fragment was subcloned into the pCDNA3 (Invitrogen) vector for DNA sequencing analysis.
[0046] Nucleotide and deduced amino acid sequence of human GPCRxII (SEQ ID NO 1) l36 GTA GGAAACGGG TTTGTGCTC TGGCTCCTG GGCTTCCGC ATGCGC
lso [0047] Amino acid sequence of human GPCRxII (330 amino acids) (SEQ ID N0:2). The seven predicted transmembrane domaines are underlined.
MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPVFLILFIALVGLVGNGFVLWLLGFRM
RRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAYLAGLS
MLSTVSTERCLSVLWPIWYRCRRPRHLSAVVCVLLWALSLLLSILEGKFCGFLFSDGDS
GWCQTFDFITAAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRLYLTILLTVLVFLLCG
LPFGIQWFLILWIWKDSDVLFCHIHPVSWLSSLNSSANPIIYFFVGSFRKQWRLQQPI
LKLALQRALQDTAEVDHSEGCFRQGTPEMSRSSLV
(G-protein coupled receptor) the following approach was used. Sequences of the following GPCR: GPR8, ChemR23, HM74 and GPR14 were used as queries to search for homologies in public high-throughput genomic sequence databases (NCBI).
[0043] Using the above strategies, a novel human sequence of GPCR was identified. We called this new GPCR:
GPCRxll (SEQ ID number 1 and 2).
[0044] Tn order to clone the GPCRxII sequence we performed a polymerase chain reaction (PCR) on total human genomic DNA. Primers were synthetized based upon the GPCRxll human sequence and were as follows:
SEQ ID 23 GPCRxII fw: 5'-ccggaattcaccatggatccaaccaccccg-3' SEQ ID 24 GPCRxII rv: 5'-ctagtctagactctacaccagactgcttctc-3' [0045] Amplification resulted in a fragments of 0.99 kilobase containing the entire coding sequence of the GPCRxIl gene. This fragment was subcloned into the pCDNA3 (Invitrogen) vector for DNA sequencing analysis.
[0046] Nucleotide and deduced amino acid sequence of human GPCRxII (SEQ ID NO 1) l36 GTA GGAAACGGG TTTGTGCTC TGGCTCCTG GGCTTCCGC ATGCGC
lso [0047] Amino acid sequence of human GPCRxII (330 amino acids) (SEQ ID N0:2). The seven predicted transmembrane domaines are underlined.
MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPVFLILFIALVGLVGNGFVLWLLGFRM
RRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAYLAGLS
MLSTVSTERCLSVLWPIWYRCRRPRHLSAVVCVLLWALSLLLSILEGKFCGFLFSDGDS
GWCQTFDFITAAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRLYLTILLTVLVFLLCG
LPFGIQWFLILWIWKDSDVLFCHIHPVSWLSSLNSSANPIIYFFVGSFRKQWRLQQPI
LKLALQRALQDTAEVDHSEGCFRQGTPEMSRSSLV
[0048] At the amino acid sequence level, the human GPCRxII is 37% identical to the rat RTA receptor. The gene coding GPCRxl1 is located on chromosome 11.
Alignment of GPCRxII (fig. l) [0049] Alignment of the amino acid sequence of GPCRxl1 with RTA and other RTA related sequences were performed using ClustalX algorithm. Then, the dendrogram was constucted using TreeView algorithm.
GPRI
l vt~ ~
Tissular distribution of GPCRxl2 [0050] Reverse transcription-polymerase chain reaction (RT-PCR) experiments were carried out using a panel of polyA~ RNA (Clontech). The primers were as follows: GPCRxll sense primer (SEQ ID NO 25: 5'-TTCTCTGTCTACGTCCTCAG-3') and GPCRxII antisense primer (SEQ
ID NO 26: 5'-GTCCTGTCATCTCTTAACAG-3'). The expected size of the amplified DNA band was 586 bp. Approximately 75 ng of poly A+ RNA was reverse transcribed with superscript II
(Life Technologies) and used for PCR. PCR was performed under the following conditions: denaturation at 94°C for 3 mina 38 cycles at 94°C for 1 min, 58°C for 2 min and 72°C
for 2 min. Aliquots (10 ~.l) of the PCR reaction were analysed by 1o agarose gel electrophoresis.
(0051] GPCRxIl mRNA was assayed by RT-PCR in 16 human tissues. A strong band of expected sire (586 bp) was detected in testis, at lower levels in uterus and thymus, while not in pituitary gland, spinal cord, pancreas, small 5 intestine, placenta, stomach, liver, lung, spleen, brain, heart, kidney and skeletal muscle.
Functional assay for GPCRxII
(0052] GPCRxII expressing clones have been obtained by transfection of CHO-K1 cells coexpressing mitochondrial 10 apoaequorin and Galphal6, limit dilution and selection by northern blotting. Positive clones were used for screening with a reference peptidic library containing 250 peptides and neuropeptides at a concentration of 100 nM. A specific activity was obtained with angiopeptin (D-NaI-Cys-Tyr-D-15 trp-Lys-Val-Cys-Thr-NH2 with a disulfide bridge between the two cysteines) and confirmed by a dose respone curve (see figure 1). Additional related peptides were tested using the same cells. Amongst the different peptides tested, somatostatin analog (D2-NaI-Cys-Tyr-D-trp-Lys-Val-Cys-D2-NaI-NH2) exhibited similar affinity. Somatostatin 14 has no activity on GPCRxll.
Material. All chemicals were obtained from Sigma, unless stated. The cell culture media were from Gibco BRL and the peptides from bachem Aequorin assays. CHO-K1 cell lines expressing GPCRxll receptors, Galphal6 and mitochondrial apoaequorin were established. A functional assay based on the luminescence of mitochondrial aequorin following intracellular Caz+
release (1) was performed as described (2). Briefly, cells were collected from plates with PBS containing 5 mM EDTA, pelleted and resuspended at 5 X 106 cells/ml in DMEM-F12 medium, incubated with 5 ~.M Coelenterazine H (Molecular Probes) for 4 hours at room temperature. Cells were then washed in DMEM-F12 medium and resuspended at a concentration of 0.5 X 106 cells/ml. Cells were then mixed with the peptides and the light emission recorded during 30 sec. using a Microlumat luminometer (Perkin Elmer). Results are expressed as Relative Light Units (RLU).
Antibodies [0053] Antibodies directed against GPCRxl1 have been produced by repeated injections of plasmid encoding GPCRxll to mice. Serum has been collected following 5 injections and used for flow cytometry analysis with cells transfected with GPCRxll. Several sera were positive and can be used for immunohistochemistry and other related applications Example 2 Cloning of the other sequences related to G-protein-coupled receptors [0054] In order to identify and clone novel human DNA
sequences related to GPCR, the following approche was used.
Sequences of the following GPCR: GPR8, ChemR23, HM74 and GPR14 were used as queries to search for homologies in public high-throughput genomic sequence databases (NCBI).
[0055] Using the above strategies, ten novel human sequences of GPCR were identified. None of these clones contain introns .
GPCRx2, SEQ ID NO 3 GPCRxS, SEQ ID NO 5 GPCRx7, SEQ ID NO 7 GPCRx9, SEQ ID NO 9 GPCRxI4, SEQ ID NO 11 GPCRxI6, SEQ ID NO 13 GPCRxl7, SEQ ID NO 15 GPCRxI8, SEQ ID NO 17 GPCRxI9, SEQ ID NO 19 GPCRx20, SEQ ID NO 21 [0056] In order to clone these GPCRx sequences, a polymerase chain reaction (PCR) was performed on total human genomic DNA. Primers were synthetized based upon the human sequences described above and were as follows:
SEQ ID NO 27 GPCRx2 fw: 5'-ccggaattcaccatggagtcctcacccatc-3' SEQ ID NO 28 GPCRx2 rv: 5'-ctagtctagacatcatgactccagccggg-3' SEQ ID NO 29 GPCRx5 fw: 5'-ccggaattcaccatggatccaaccatctcaacc-3' SEQ ID NO 30 GPCRx5 rv: 5'-ctagtctagatcactgctccaatctgcttc-3' SEQ ID NO 31 GPCRx7 fw:
5'-ccggaattcaccatgaaccagactttgaatagcagtgg-3' SEQ ID NO 32 GPCRx7 rv:
5'-ctagtctagatctcaagcccccatctcattggtgccc-3' SEQ ID NO 33 GPCRx9 fw: 5'-ccggaattcaccatggaagctgacctgg-3' SEQ ID NO 34 GPCRx9 rv: 5'-ctagtctagactcacgtggggcctgcgcc-3' SEQ ID NO 35 GPCRxI4 fw: 5'-ccggaattcgccatgtacaacgggtcg-3' SEQ ID NO 36 GPCRxI4 rv: 5'-ctagtctagattcagtgccactcaacaatg-3' [0057] Amplification resulted in a fragments of approximately 1 - 1.5 kilobase containing the entire coding sequence of the human genes. These fragments obtained were subcloned into the pCDNA3 (Invitrogen) vector for DNA
sequencing analysis.
Tissue distribution of identified (GPCRx) receptors [0058] To determine the tissue distribution of different GPCRx mRNA, reverse transcriptase-polymerase chaine reaction (RT-PCR) were performed with 200 ng of mRNA
isolated from human tissues (Clontech). The oligo(dT) primer was used in the reverse transcription step. Then, different GPCRx cDNA were amplified with specifics primers.
GPCRx GPCRx GPCRx GPCRx GPCRx GPCRx GPCRxGPCRx GPCRx Li _ _ _ _ _ _ _ _ +
Lu .+. _ + + - ++ - - ++
/
_ Sp _ - ++ + - _ _ _ +
Te - + - ++ - ++ - -I-/- +
Br ++ - - - - - ++ - ++
He _ _ _ _ _ _ _ - ++
Ki +/ - - + - ++ - - +
_ Sk.m _ _ _ _ _ + _ - ++
Pi.G _ - - - - - ++ +/- +
Sp.C ++ _ - - - ++ +/- +/- +~-Th +/ - + - - +-I- - - ++
_ Pa _ _ _ _ - ++ .+/ _ -_ S +/ - + - - ++ - - +
. _ In Ut _ _ _ _ _ .+.+ _ +/ +, _ P1 - - - ++ ++ - - - +
St - - + +/- - ..~+ - - +
Table l: Tissue distribution of GPCRxs: The presence or absence of differents GPCRx was determined by RT-PCR
analysis. ++, strong signal; +, signal clearly detected;
+/-, weak signal; -, signal not detected. The tissues are the following: Li, liver; Lu, lung; Sp, Spleen; Te, testis;
Br, Brain; He, Heart; Ki, Kidney; Sk.M, Skeletal muscle;
Pi.G, Pituitary gland; Sp.C, spinal cord; Th, Thymus; Pa, Pancreas; S.In, Small intestine; Ut, Uterus; Pl, Plancenta;
St, Stomach.
Alignment of GPCRxII (fig. l) [0049] Alignment of the amino acid sequence of GPCRxl1 with RTA and other RTA related sequences were performed using ClustalX algorithm. Then, the dendrogram was constucted using TreeView algorithm.
GPRI
l vt~ ~
Tissular distribution of GPCRxl2 [0050] Reverse transcription-polymerase chain reaction (RT-PCR) experiments were carried out using a panel of polyA~ RNA (Clontech). The primers were as follows: GPCRxll sense primer (SEQ ID NO 25: 5'-TTCTCTGTCTACGTCCTCAG-3') and GPCRxII antisense primer (SEQ
ID NO 26: 5'-GTCCTGTCATCTCTTAACAG-3'). The expected size of the amplified DNA band was 586 bp. Approximately 75 ng of poly A+ RNA was reverse transcribed with superscript II
(Life Technologies) and used for PCR. PCR was performed under the following conditions: denaturation at 94°C for 3 mina 38 cycles at 94°C for 1 min, 58°C for 2 min and 72°C
for 2 min. Aliquots (10 ~.l) of the PCR reaction were analysed by 1o agarose gel electrophoresis.
(0051] GPCRxIl mRNA was assayed by RT-PCR in 16 human tissues. A strong band of expected sire (586 bp) was detected in testis, at lower levels in uterus and thymus, while not in pituitary gland, spinal cord, pancreas, small 5 intestine, placenta, stomach, liver, lung, spleen, brain, heart, kidney and skeletal muscle.
Functional assay for GPCRxII
(0052] GPCRxII expressing clones have been obtained by transfection of CHO-K1 cells coexpressing mitochondrial 10 apoaequorin and Galphal6, limit dilution and selection by northern blotting. Positive clones were used for screening with a reference peptidic library containing 250 peptides and neuropeptides at a concentration of 100 nM. A specific activity was obtained with angiopeptin (D-NaI-Cys-Tyr-D-15 trp-Lys-Val-Cys-Thr-NH2 with a disulfide bridge between the two cysteines) and confirmed by a dose respone curve (see figure 1). Additional related peptides were tested using the same cells. Amongst the different peptides tested, somatostatin analog (D2-NaI-Cys-Tyr-D-trp-Lys-Val-Cys-D2-NaI-NH2) exhibited similar affinity. Somatostatin 14 has no activity on GPCRxll.
Material. All chemicals were obtained from Sigma, unless stated. The cell culture media were from Gibco BRL and the peptides from bachem Aequorin assays. CHO-K1 cell lines expressing GPCRxll receptors, Galphal6 and mitochondrial apoaequorin were established. A functional assay based on the luminescence of mitochondrial aequorin following intracellular Caz+
release (1) was performed as described (2). Briefly, cells were collected from plates with PBS containing 5 mM EDTA, pelleted and resuspended at 5 X 106 cells/ml in DMEM-F12 medium, incubated with 5 ~.M Coelenterazine H (Molecular Probes) for 4 hours at room temperature. Cells were then washed in DMEM-F12 medium and resuspended at a concentration of 0.5 X 106 cells/ml. Cells were then mixed with the peptides and the light emission recorded during 30 sec. using a Microlumat luminometer (Perkin Elmer). Results are expressed as Relative Light Units (RLU).
Antibodies [0053] Antibodies directed against GPCRxl1 have been produced by repeated injections of plasmid encoding GPCRxll to mice. Serum has been collected following 5 injections and used for flow cytometry analysis with cells transfected with GPCRxll. Several sera were positive and can be used for immunohistochemistry and other related applications Example 2 Cloning of the other sequences related to G-protein-coupled receptors [0054] In order to identify and clone novel human DNA
sequences related to GPCR, the following approche was used.
Sequences of the following GPCR: GPR8, ChemR23, HM74 and GPR14 were used as queries to search for homologies in public high-throughput genomic sequence databases (NCBI).
[0055] Using the above strategies, ten novel human sequences of GPCR were identified. None of these clones contain introns .
GPCRx2, SEQ ID NO 3 GPCRxS, SEQ ID NO 5 GPCRx7, SEQ ID NO 7 GPCRx9, SEQ ID NO 9 GPCRxI4, SEQ ID NO 11 GPCRxI6, SEQ ID NO 13 GPCRxl7, SEQ ID NO 15 GPCRxI8, SEQ ID NO 17 GPCRxI9, SEQ ID NO 19 GPCRx20, SEQ ID NO 21 [0056] In order to clone these GPCRx sequences, a polymerase chain reaction (PCR) was performed on total human genomic DNA. Primers were synthetized based upon the human sequences described above and were as follows:
SEQ ID NO 27 GPCRx2 fw: 5'-ccggaattcaccatggagtcctcacccatc-3' SEQ ID NO 28 GPCRx2 rv: 5'-ctagtctagacatcatgactccagccggg-3' SEQ ID NO 29 GPCRx5 fw: 5'-ccggaattcaccatggatccaaccatctcaacc-3' SEQ ID NO 30 GPCRx5 rv: 5'-ctagtctagatcactgctccaatctgcttc-3' SEQ ID NO 31 GPCRx7 fw:
5'-ccggaattcaccatgaaccagactttgaatagcagtgg-3' SEQ ID NO 32 GPCRx7 rv:
5'-ctagtctagatctcaagcccccatctcattggtgccc-3' SEQ ID NO 33 GPCRx9 fw: 5'-ccggaattcaccatggaagctgacctgg-3' SEQ ID NO 34 GPCRx9 rv: 5'-ctagtctagactcacgtggggcctgcgcc-3' SEQ ID NO 35 GPCRxI4 fw: 5'-ccggaattcgccatgtacaacgggtcg-3' SEQ ID NO 36 GPCRxI4 rv: 5'-ctagtctagattcagtgccactcaacaatg-3' [0057] Amplification resulted in a fragments of approximately 1 - 1.5 kilobase containing the entire coding sequence of the human genes. These fragments obtained were subcloned into the pCDNA3 (Invitrogen) vector for DNA
sequencing analysis.
Tissue distribution of identified (GPCRx) receptors [0058] To determine the tissue distribution of different GPCRx mRNA, reverse transcriptase-polymerase chaine reaction (RT-PCR) were performed with 200 ng of mRNA
isolated from human tissues (Clontech). The oligo(dT) primer was used in the reverse transcription step. Then, different GPCRx cDNA were amplified with specifics primers.
GPCRx GPCRx GPCRx GPCRx GPCRx GPCRx GPCRxGPCRx GPCRx Li _ _ _ _ _ _ _ _ +
Lu .+. _ + + - ++ - - ++
/
_ Sp _ - ++ + - _ _ _ +
Te - + - ++ - ++ - -I-/- +
Br ++ - - - - - ++ - ++
He _ _ _ _ _ _ _ - ++
Ki +/ - - + - ++ - - +
_ Sk.m _ _ _ _ _ + _ - ++
Pi.G _ - - - - - ++ +/- +
Sp.C ++ _ - - - ++ +/- +/- +~-Th +/ - + - - +-I- - - ++
_ Pa _ _ _ _ - ++ .+/ _ -_ S +/ - + - - ++ - - +
. _ In Ut _ _ _ _ _ .+.+ _ +/ +, _ P1 - - - ++ ++ - - - +
St - - + +/- - ..~+ - - +
Table l: Tissue distribution of GPCRxs: The presence or absence of differents GPCRx was determined by RT-PCR
analysis. ++, strong signal; +, signal clearly detected;
+/-, weak signal; -, signal not detected. The tissues are the following: Li, liver; Lu, lung; Sp, Spleen; Te, testis;
Br, Brain; He, Heart; Ki, Kidney; Sk.M, Skeletal muscle;
Pi.G, Pituitary gland; Sp.C, spinal cord; Th, Thymus; Pa, Pancreas; S.In, Small intestine; Ut, Uterus; Pl, Plancenta;
St, Stomach.
Reference 1. Stables, J., A. Green, F. Marshall, N. Fraser, E.
Knight, M. Sautel, G. Milligan, M. Lee, and S. Rees.
1997. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal.
Biochem. 252:115-126.
2. Blanpain, C., I. Migeotte, B. Lee, J. Vakili, B.J.
Doran~, C. Govaerts, G. Vassart, R.W. Doms, and M.
Parmentier. 1999 CCRS binds multiple CC-chemokines: MCP
3 acts as a natural antagonist. Blood 94:1899-1905.
Nucleotide sequence human 3 and and of GPCRx2 4 deduced (SEQ
amino ID
acid NO:
respectively) 9l GTCCCG GAGGTGGGG CTACGG GATGTTGCT TCGGAATCT GTGGCC 135 406,E P P A V D F R I P G Q I A E 420 451 S * 452 Amino acid sequence of human GPCRx2 (451 amino acids) (SEQ ID N~: 4). The seven predicted transmembrane domaines are underlined.
MESSPIPQSSGNSSTLGRVPQTPGPSTASGVPEVGLRDVASESVALFFMLLLDLTAVAGNAAVMAVIAKTPALRKFV_F
'VF
HLCLVDLLAALTLMPLAMLSSSALFDHALFGEVACRLYLFLSVCFVSLAILSVSAINVERYYYVVHPMRYEVRMTLGLV
A
SVLVGVWKALAMASVPVLGRVSWEEGAPSVPPGCSLQWSHSAYCQLFWVFAVLYFLLPLLLILVWCSMFRVARVAAM
QHGPLPTWMETPRQRSESLSSRSTMVTSSGAPQTTPHRTFGGGKAAWLLAVGGQFLLCWLPYFSFHLWALSAQPISTG
QVESWTWIGYFCFTSNPFFYGCLNRQIRGELSKQFVCFFKPAPEEELRLPSREGSIEENFLQFLQGTGCPSESWVSRPL
PSPKQEPPAVDFRIPGQIAEETSEFLEQQLTSDIIMSDSYLRPAASPRLES
At the amino acid sequence level, the human GPCRx2 is 23o identical to the human histamine H2 receptor.
~G
Nucleotide acidsequence human 5 and and of GPCRx5 6 deduced (SEQ
amino ID
NO:
respectively) l81 V A W L I F L C V V L C G S S 195 316S G S R L E Q * 323 Amino acid sequence of human GPCRx5 (322 amino acids) (SEQ ID N0:6) . The seven predicted transmembrane domaines are underlined.
MDPTISTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNAVVLWLLGCRMRRNAFSIYILNLAAADFLFLSGR
L
IYSLLSFISIPHTISKILYPVMMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAWCVLLWALSLLRSILEWML
CGFLFSGADSAWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILLTVLVFLLCGLPFGIQFFLF
L
WIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQRQNRQNLKLVLQRALQDASEVDEGGGQLPEEILELSGSR
L
EQ
At the amino acid sequence level, the human GPCRxS is 31% identical to the human mas receptor.
Nucleotide acidsequence human 7 and and of GPCRx7 8 deduced (SEQ
amino ID
NO:
respectively) 316T N E M G A * 322 Amino acid sequence of human GPCRx7 (321 amino acids) (SEQ ID N0:8). The seven predicted transmembrane domaines are underlined.
MNQTLNSSGTVESALNYSRGSTVHTAYLVLSSLAMFTCLCGMAGNSMVIWLLGFRMHRNPFCIYILNLAAADLLFLFSM
A
STLSLETQPLVNTTDKVHELMKRLMYFAYTVGLSLLTAISTQRCLSVLFPIWfKCHRPRHLSAWVCGLLWTLCLLMNGL
T
SSFCSKFLKFNEDRCFRVDMVQAALIMGVLTPVMTLSSLTLFVWVRRSSQQWRRQPTRLFVVVLASVLVFLICSLPLSI
Y
WFVLYWLSLPPEMQVLCFSLSRLSSSVSSSANPVIYFLVGSRRSHRLPTRSLGTVLQQALREEPELEGGETPTVGTNEM
G
A
At the amino acid sequence level, the human GPCRx7 is 29o identical to the rat RTA receptor.
Nucleotide acidsequence human 9 and and of GPCRx9 10 deduced (SEQ
amino ID
NO:
respectively) 136 ATG GCGTGGCTG GCCGGCTCC CAGGCCCGGCAT GGAGCTGGC ACG l80 GCC TAC AGC
AGC CTC CGG
CTG GTG TGC
CGG AGC CAG
TCT CCA GCC
CAG CCT ACA
CCA GAT CCT
CAG TCG AAC
GCC CAG GCA
AAC ACC CCC
TGT GCT ACC
GCC GAC GGA
CCC ACC GGC
466 T * 467 TGA
Amino f humanGPCRx9 (466amino cids) . The acid a (SEQ six sequence ID
o N0:10) predictedtransmembrane domaines are underlined.
MEADLGATGHRPRTELDDEDSYPQGGWDTVFLVALLLLGLPANGLMAWLAGSQARHGAGTRLALLLLSLALSDFLFLAA
A
A_FQILEIRHGGHWPLGTAACRFYYFLWGVSYSSGLFLLAALSLDRCLLALCPHWYPGHRPVRLPLWVCAGVWVLATLF
SV
PWLVFPEAAVWWYDLVICLDFWDSEELSLRMLEVLGGFLPFLLLLVCHVLTQATACRTCHRQQQPAACRGFARVARTIL
S
AYVVLRLPYQLAQLLYLAFLWDVYSGYLLWEALVYSDYLILLNSCLSPFLCLMASADLRTLLRSVL
SSFAAALCEERPGS
FTPTEPQTQLDSEGPTLPEPMAEAQSQMDPVAQPQVNPTLQPRSDPTAQP
QLNPTAQPQSDPTAQP QLNLMAQPQSDSVA
QPQADTNVQTPAPAASSVPSPCDEASPTPS SHPTPGALEDPATPPASEGE
SPSSTPPEAAPGAGPT
At the no acidsequence el,the human is 33aidentical the human ami lev GPCRx9 to ChemR23 receptor.
Nucleotide acid GPCRxI4 (SEQID 11 and sequence NO: and deduced of amino human 12 respectively) TCA TTT
AGT AAG
GAA ATT
GTG TTC
331 ~Q S Q S D G Q W D P H I V E W 345 CAC TGG
346 H * 347 Amino acid sequence of human GPCRxI4 (346 (SEQ ID N0:12).The amino acids) seven predicted transmembrane domaines are underlined.
MYNGSCCRIEGDTISQVMPPLLIVAFVLGALGNGVALCGFCFHMKTWKPSTVYLFNLAVADFLLMICLPFRTDYYLRRR
H
WAFGDIPCRVGLFTLAMNRAGSIVFLTWAADRYFKVVHPHHAVNTISTRVAAGIVCTLWALVILGTVYLL
LENHLCVQE
TAVSCESFIMESANGWHDIMFQLEFFMPLGIILFCSFKIVWSLRRRQQLARQARMKKATRFIMVVAIVFITCYLPSVSA
R
LYFLWTVPSSACDPSVHGALHITLSFTYMNSMLDPLVYYFSSPSFPKFYNKLKICSLKPKQPGHSKTQRPEEMPISNLG
R
RSCISVANSFQSQSDGQWDPHIVEWH
At the amino acid sequence level, the human 50o identical the GPCRxI4 is to human HM74 receptor.
Nucleotide acidsequence human ID 13 and of GPCRxI6 N0: and deduced (SEQ
amino 14 respectively). This tidesequence located on the chromosome4.
nucleo is 136 GTGAAT CTGTCT CTGGGCCAC CTGCTG'CTGGCGGCGCTG GACATG 180 91 S N A A L S V A A h 5 A D Q W 105 27l TCCAAC GCGGCG CTGAGCGTG GCGGCGCTG AGCGCAGAC CAGTGG 315 7.06 L A V G F P L R Y A G R L R P 120 301R A V G C A S P G G V P R A L 3l5 346M D L G F K S * 352 1036ATG GACTTGGGC TTCAAG'PCTTGA 1059 Amino acid sequence of human GPCRxl6 (352 amino acids) (SEQ ID N0: 14). The six predicted transmembrane domaines are underlined.
MGPGEALLAGLLVMVLAVALLSNALVLLCCAYSAELRTRASGVLLVNLSLGHLLLAALDMPFTLLGVMRGRTPSAPGA_ CQ
VIGFLDTFLASNAALSVAALSADQWLAVGFPLRYAGRLRPRYAGLLLGCAWGQSLAFSGAALGCSWLGYSSAFASCSLR
L
PPEPERPRFAAFTATLHAVGFVLPLAVLCLTSLQVHRVARRHCQRMDTVTMKALALLADLHPRYWPSACRQAQARDLGA
P
WAVGLRSLWASPPLLCPEFTSHSTAPARCSQGFPVGSLVQTLRGPLPPGICAHSAQGALRRAVGCASPGGVPRALLWAA
R
HTPPVHGCGSEASACFCPLLTQCPCMDLGFKS
At the amino acid sequence level, the human GPCRxI6 is 50o identical to the rat GPR 26 receptor.
Nucleotide and deduced amino acid sequence of human GPCRxI7 (SEQ TD N0: 1S and 16 respectively). This nucleotide sequence is located on the chromosome 2.
241 A T' L L L S V L A Y E Q R P P 255 GCA
CCC
GAG
316T T Q A A K A V S T W T * 327 GCA
Amino acid sequence of human GPCRxI7 (327 amino acids) (SEQ TD N0:16). The seven predicted transmembrane domaines are underlined.
MTPNSTGEVPSPIPKGALGLSLALASLIITANLLLALGIAGTAACAATCWLLLPEPTAGWAAHGSGIATLPGLWNQSRR
G
YWSCLLVYLAPNFSFLSLLANLLLVHGERYMAVLRPLQPPGSIRLALLLTWAGPLLFASLPALGWNHWTPGANCSSQAI
F
PAPYLYLEVYGLLLPAVGAAAFLSVRVLATAHRQLQDICRLERAVCRDEPSALARALTWRQARAQAGAMLLFGLCWGPY
V
ATLLLSVLAYEQRPPLGPGTLLSLLSLGSASAAAVPVAMGLGDQRYTAPWRQPPKGACRGCGEEPPGTVPAPALPTTQA
A
At the amino acid sequence level, the human GPCRxI7 is 28's identical to the human EDGE receptor 34 ' Nucleotide acidsequence human ID 17 and of GPCRxl8 NO: and deduced (SEQ
amino 18 respectively). This tidesequence located on the chromosome 2.
nucleo is TCC GTG
ACT CTC
CTT ATG
CAG ATG
CAG ACC
346 I S * 347 Amino acid sequence of human GPCRxI8 (347 (SEQ ID N0:18).The amino acids) seven predicted transmembrane domaines are underlined.
MGDELAPCPVGTTAWPALIQLISKTPCMPQAASNTSLGLGDLRVPSSMLYWLFLPSSLLAAATLAVSPLLLVTILRNQR
L
RQEPHYLLPANILLSDLAYILLHMLISSSSLGGWELGRMACGILTDAVFAACTSTILSFTAIVLHTYLAVT
HPLRYLSFM
SHGAAWKAVALIWLVACCFPTFLIWLSKWQDAQLEEQGASYILPPSMGTQPGCGLLVIVTYTSILCVLFLC
TALIANCFW
RIYAEAKTSGIWGQGYSRARGTLLIHSVLITLYVSTGWFSLDMVLTRYHHIDSGTHTWLLAANSEVLMMLPRAMLTYLY
LLRYRQLLGMVRGHLPSRRHQAIFTIS
At the amino acid sequence level, the human 25% identical the GPCRxIB is to rabbit 5HT1D-(3 receptor.
Nucleotide acid sequence) GPCR.xl9 and sequence of deduced (partial human amino (SEQ 9 respective ly).This tidesequenc e locatedon ID NO: and nucleo is the chromosome .
271 TCCATCCAC ACCTCC ATATGGATTACT GTACCG TTAACCATTGAC 3l5 331 V S P * 333 Partial amino acid sequence of human GPCRxI9 (333 amino acids) (SEQ ID N0:20).
The seven predicted transmembrane domaines are underlined.
GPHRSQRSHLCFRAKPVFLLSTANILTVIILSQLVARRQKSSYNYLLALAAADILVLFFIVFVDFLLEDFILNMQMPQV
P
DKIIEVLEFSSIHTSIWITVPLTIDRYIAVCHPLKYHTVSYPARTRKVIVSVYITCFLTSIPYYWWPNIWTEDYISTSV
H
HVLIWIHCFTVYLVPCSIFFILNSIIVYKLRRKSNFRLRGYSTGKTTAILFTITSIFATLWAPRIIMILYHLYGAPIQN
_R
WLVHIMSDIANMLALLNTAINFFLYCFISKRFRTMAAATLKAFFKCQKQPVQFYTNHNFSITSSPWISPANSHCIKMLV
Y
QYDKNGKPIKVSP
At the amino acid sequence level, the human GPCRxI9 is 25o identical to the C.
EleganS F21C10.9 G-protein coupled receptor.
3a Nucleotide acid GPCRx20 (SEQ 21 and sequence ID and deduced of N0:
amino human 22 respectively) . s cated thechromosome 5.
This lo on nucleotide sequence i l M L A A A F A D S N S S S M N 15 GCT CCG CAA
GTC TTT TCA
GTG GAA GAA
TGG ACC CCA
ACA GGC GGT
CCA CCA CCA CCA
AGC CCC GGC ACT
CCC CTT GTA TGG
GTC TCT GAC ATC
406 P W E H E D Q E T G E G V K * 419 GAT GAG GAA TAG
Amino acid sequence of human amino acids)(SEQ ID N0:22).The seven GPCRx20 (419 predicted transmembrane domaines are underlined.
MLAAAFADSNSSSMNVSFAHLHFAGGYLPSDSQDWRTITPALLVAVCLVGFVGNLCVIGILLHNAWKGKPS
MIHSlILNL
SLADLSLLLFSAPIRATAYSKSVWDLGWFVCKSSDWFIHTCMAAKSLTIVWAKVCFMYASDPAKQVSIHN
YTIWSVLVA
IWTVASLLPLPEWFFSTIRHHEGVEMCLVDVPAVAEEFMSMFGKLYPLLAFGLPLFFASFYFWRAYDQCKKRGTKTQNL
R
NQTRSKQVTVMLLSIAIISALLWLPEWVAWLWVWHLKAAGPAPPQGFIALSQVLMFSISSANPLIFLVMSE
EFREGLKGV
WKWMITKKPPTVSESQETPAGNSEGLPDKVPSPESPASTPEKEKPSSPSSGKGKTEKAEIPILPDVEQFWHERDTVPSV
Q
DNDPIPWEHEDQETGEGVK
At the amino acid sequence the 20s identical the level, human to GPCRx20 is mouse galanin 2 receptor.
Knight, M. Sautel, G. Milligan, M. Lee, and S. Rees.
1997. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal.
Biochem. 252:115-126.
2. Blanpain, C., I. Migeotte, B. Lee, J. Vakili, B.J.
Doran~, C. Govaerts, G. Vassart, R.W. Doms, and M.
Parmentier. 1999 CCRS binds multiple CC-chemokines: MCP
3 acts as a natural antagonist. Blood 94:1899-1905.
Nucleotide sequence human 3 and and of GPCRx2 4 deduced (SEQ
amino ID
acid NO:
respectively) 9l GTCCCG GAGGTGGGG CTACGG GATGTTGCT TCGGAATCT GTGGCC 135 406,E P P A V D F R I P G Q I A E 420 451 S * 452 Amino acid sequence of human GPCRx2 (451 amino acids) (SEQ ID N~: 4). The seven predicted transmembrane domaines are underlined.
MESSPIPQSSGNSSTLGRVPQTPGPSTASGVPEVGLRDVASESVALFFMLLLDLTAVAGNAAVMAVIAKTPALRKFV_F
'VF
HLCLVDLLAALTLMPLAMLSSSALFDHALFGEVACRLYLFLSVCFVSLAILSVSAINVERYYYVVHPMRYEVRMTLGLV
A
SVLVGVWKALAMASVPVLGRVSWEEGAPSVPPGCSLQWSHSAYCQLFWVFAVLYFLLPLLLILVWCSMFRVARVAAM
QHGPLPTWMETPRQRSESLSSRSTMVTSSGAPQTTPHRTFGGGKAAWLLAVGGQFLLCWLPYFSFHLWALSAQPISTG
QVESWTWIGYFCFTSNPFFYGCLNRQIRGELSKQFVCFFKPAPEEELRLPSREGSIEENFLQFLQGTGCPSESWVSRPL
PSPKQEPPAVDFRIPGQIAEETSEFLEQQLTSDIIMSDSYLRPAASPRLES
At the amino acid sequence level, the human GPCRx2 is 23o identical to the human histamine H2 receptor.
~G
Nucleotide acidsequence human 5 and and of GPCRx5 6 deduced (SEQ
amino ID
NO:
respectively) l81 V A W L I F L C V V L C G S S 195 316S G S R L E Q * 323 Amino acid sequence of human GPCRx5 (322 amino acids) (SEQ ID N0:6) . The seven predicted transmembrane domaines are underlined.
MDPTISTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNAVVLWLLGCRMRRNAFSIYILNLAAADFLFLSGR
L
IYSLLSFISIPHTISKILYPVMMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAWCVLLWALSLLRSILEWML
CGFLFSGADSAWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILLTVLVFLLCGLPFGIQFFLF
L
WIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQRQNRQNLKLVLQRALQDASEVDEGGGQLPEEILELSGSR
L
EQ
At the amino acid sequence level, the human GPCRxS is 31% identical to the human mas receptor.
Nucleotide acidsequence human 7 and and of GPCRx7 8 deduced (SEQ
amino ID
NO:
respectively) 316T N E M G A * 322 Amino acid sequence of human GPCRx7 (321 amino acids) (SEQ ID N0:8). The seven predicted transmembrane domaines are underlined.
MNQTLNSSGTVESALNYSRGSTVHTAYLVLSSLAMFTCLCGMAGNSMVIWLLGFRMHRNPFCIYILNLAAADLLFLFSM
A
STLSLETQPLVNTTDKVHELMKRLMYFAYTVGLSLLTAISTQRCLSVLFPIWfKCHRPRHLSAWVCGLLWTLCLLMNGL
T
SSFCSKFLKFNEDRCFRVDMVQAALIMGVLTPVMTLSSLTLFVWVRRSSQQWRRQPTRLFVVVLASVLVFLICSLPLSI
Y
WFVLYWLSLPPEMQVLCFSLSRLSSSVSSSANPVIYFLVGSRRSHRLPTRSLGTVLQQALREEPELEGGETPTVGTNEM
G
A
At the amino acid sequence level, the human GPCRx7 is 29o identical to the rat RTA receptor.
Nucleotide acidsequence human 9 and and of GPCRx9 10 deduced (SEQ
amino ID
NO:
respectively) 136 ATG GCGTGGCTG GCCGGCTCC CAGGCCCGGCAT GGAGCTGGC ACG l80 GCC TAC AGC
AGC CTC CGG
CTG GTG TGC
CGG AGC CAG
TCT CCA GCC
CAG CCT ACA
CCA GAT CCT
CAG TCG AAC
GCC CAG GCA
AAC ACC CCC
TGT GCT ACC
GCC GAC GGA
CCC ACC GGC
466 T * 467 TGA
Amino f humanGPCRx9 (466amino cids) . The acid a (SEQ six sequence ID
o N0:10) predictedtransmembrane domaines are underlined.
MEADLGATGHRPRTELDDEDSYPQGGWDTVFLVALLLLGLPANGLMAWLAGSQARHGAGTRLALLLLSLALSDFLFLAA
A
A_FQILEIRHGGHWPLGTAACRFYYFLWGVSYSSGLFLLAALSLDRCLLALCPHWYPGHRPVRLPLWVCAGVWVLATLF
SV
PWLVFPEAAVWWYDLVICLDFWDSEELSLRMLEVLGGFLPFLLLLVCHVLTQATACRTCHRQQQPAACRGFARVARTIL
S
AYVVLRLPYQLAQLLYLAFLWDVYSGYLLWEALVYSDYLILLNSCLSPFLCLMASADLRTLLRSVL
SSFAAALCEERPGS
FTPTEPQTQLDSEGPTLPEPMAEAQSQMDPVAQPQVNPTLQPRSDPTAQP
QLNPTAQPQSDPTAQP QLNLMAQPQSDSVA
QPQADTNVQTPAPAASSVPSPCDEASPTPS SHPTPGALEDPATPPASEGE
SPSSTPPEAAPGAGPT
At the no acidsequence el,the human is 33aidentical the human ami lev GPCRx9 to ChemR23 receptor.
Nucleotide acid GPCRxI4 (SEQID 11 and sequence NO: and deduced of amino human 12 respectively) TCA TTT
AGT AAG
GAA ATT
GTG TTC
331 ~Q S Q S D G Q W D P H I V E W 345 CAC TGG
346 H * 347 Amino acid sequence of human GPCRxI4 (346 (SEQ ID N0:12).The amino acids) seven predicted transmembrane domaines are underlined.
MYNGSCCRIEGDTISQVMPPLLIVAFVLGALGNGVALCGFCFHMKTWKPSTVYLFNLAVADFLLMICLPFRTDYYLRRR
H
WAFGDIPCRVGLFTLAMNRAGSIVFLTWAADRYFKVVHPHHAVNTISTRVAAGIVCTLWALVILGTVYLL
LENHLCVQE
TAVSCESFIMESANGWHDIMFQLEFFMPLGIILFCSFKIVWSLRRRQQLARQARMKKATRFIMVVAIVFITCYLPSVSA
R
LYFLWTVPSSACDPSVHGALHITLSFTYMNSMLDPLVYYFSSPSFPKFYNKLKICSLKPKQPGHSKTQRPEEMPISNLG
R
RSCISVANSFQSQSDGQWDPHIVEWH
At the amino acid sequence level, the human 50o identical the GPCRxI4 is to human HM74 receptor.
Nucleotide acidsequence human ID 13 and of GPCRxI6 N0: and deduced (SEQ
amino 14 respectively). This tidesequence located on the chromosome4.
nucleo is 136 GTGAAT CTGTCT CTGGGCCAC CTGCTG'CTGGCGGCGCTG GACATG 180 91 S N A A L S V A A h 5 A D Q W 105 27l TCCAAC GCGGCG CTGAGCGTG GCGGCGCTG AGCGCAGAC CAGTGG 315 7.06 L A V G F P L R Y A G R L R P 120 301R A V G C A S P G G V P R A L 3l5 346M D L G F K S * 352 1036ATG GACTTGGGC TTCAAG'PCTTGA 1059 Amino acid sequence of human GPCRxl6 (352 amino acids) (SEQ ID N0: 14). The six predicted transmembrane domaines are underlined.
MGPGEALLAGLLVMVLAVALLSNALVLLCCAYSAELRTRASGVLLVNLSLGHLLLAALDMPFTLLGVMRGRTPSAPGA_ CQ
VIGFLDTFLASNAALSVAALSADQWLAVGFPLRYAGRLRPRYAGLLLGCAWGQSLAFSGAALGCSWLGYSSAFASCSLR
L
PPEPERPRFAAFTATLHAVGFVLPLAVLCLTSLQVHRVARRHCQRMDTVTMKALALLADLHPRYWPSACRQAQARDLGA
P
WAVGLRSLWASPPLLCPEFTSHSTAPARCSQGFPVGSLVQTLRGPLPPGICAHSAQGALRRAVGCASPGGVPRALLWAA
R
HTPPVHGCGSEASACFCPLLTQCPCMDLGFKS
At the amino acid sequence level, the human GPCRxI6 is 50o identical to the rat GPR 26 receptor.
Nucleotide and deduced amino acid sequence of human GPCRxI7 (SEQ TD N0: 1S and 16 respectively). This nucleotide sequence is located on the chromosome 2.
241 A T' L L L S V L A Y E Q R P P 255 GCA
CCC
GAG
316T T Q A A K A V S T W T * 327 GCA
Amino acid sequence of human GPCRxI7 (327 amino acids) (SEQ TD N0:16). The seven predicted transmembrane domaines are underlined.
MTPNSTGEVPSPIPKGALGLSLALASLIITANLLLALGIAGTAACAATCWLLLPEPTAGWAAHGSGIATLPGLWNQSRR
G
YWSCLLVYLAPNFSFLSLLANLLLVHGERYMAVLRPLQPPGSIRLALLLTWAGPLLFASLPALGWNHWTPGANCSSQAI
F
PAPYLYLEVYGLLLPAVGAAAFLSVRVLATAHRQLQDICRLERAVCRDEPSALARALTWRQARAQAGAMLLFGLCWGPY
V
ATLLLSVLAYEQRPPLGPGTLLSLLSLGSASAAAVPVAMGLGDQRYTAPWRQPPKGACRGCGEEPPGTVPAPALPTTQA
A
At the amino acid sequence level, the human GPCRxI7 is 28's identical to the human EDGE receptor 34 ' Nucleotide acidsequence human ID 17 and of GPCRxl8 NO: and deduced (SEQ
amino 18 respectively). This tidesequence located on the chromosome 2.
nucleo is TCC GTG
ACT CTC
CTT ATG
CAG ATG
CAG ACC
346 I S * 347 Amino acid sequence of human GPCRxI8 (347 (SEQ ID N0:18).The amino acids) seven predicted transmembrane domaines are underlined.
MGDELAPCPVGTTAWPALIQLISKTPCMPQAASNTSLGLGDLRVPSSMLYWLFLPSSLLAAATLAVSPLLLVTILRNQR
L
RQEPHYLLPANILLSDLAYILLHMLISSSSLGGWELGRMACGILTDAVFAACTSTILSFTAIVLHTYLAVT
HPLRYLSFM
SHGAAWKAVALIWLVACCFPTFLIWLSKWQDAQLEEQGASYILPPSMGTQPGCGLLVIVTYTSILCVLFLC
TALIANCFW
RIYAEAKTSGIWGQGYSRARGTLLIHSVLITLYVSTGWFSLDMVLTRYHHIDSGTHTWLLAANSEVLMMLPRAMLTYLY
LLRYRQLLGMVRGHLPSRRHQAIFTIS
At the amino acid sequence level, the human 25% identical the GPCRxIB is to rabbit 5HT1D-(3 receptor.
Nucleotide acid sequence) GPCR.xl9 and sequence of deduced (partial human amino (SEQ 9 respective ly).This tidesequenc e locatedon ID NO: and nucleo is the chromosome .
271 TCCATCCAC ACCTCC ATATGGATTACT GTACCG TTAACCATTGAC 3l5 331 V S P * 333 Partial amino acid sequence of human GPCRxI9 (333 amino acids) (SEQ ID N0:20).
The seven predicted transmembrane domaines are underlined.
GPHRSQRSHLCFRAKPVFLLSTANILTVIILSQLVARRQKSSYNYLLALAAADILVLFFIVFVDFLLEDFILNMQMPQV
P
DKIIEVLEFSSIHTSIWITVPLTIDRYIAVCHPLKYHTVSYPARTRKVIVSVYITCFLTSIPYYWWPNIWTEDYISTSV
H
HVLIWIHCFTVYLVPCSIFFILNSIIVYKLRRKSNFRLRGYSTGKTTAILFTITSIFATLWAPRIIMILYHLYGAPIQN
_R
WLVHIMSDIANMLALLNTAINFFLYCFISKRFRTMAAATLKAFFKCQKQPVQFYTNHNFSITSSPWISPANSHCIKMLV
Y
QYDKNGKPIKVSP
At the amino acid sequence level, the human GPCRxI9 is 25o identical to the C.
EleganS F21C10.9 G-protein coupled receptor.
3a Nucleotide acid GPCRx20 (SEQ 21 and sequence ID and deduced of N0:
amino human 22 respectively) . s cated thechromosome 5.
This lo on nucleotide sequence i l M L A A A F A D S N S S S M N 15 GCT CCG CAA
GTC TTT TCA
GTG GAA GAA
TGG ACC CCA
ACA GGC GGT
CCA CCA CCA CCA
AGC CCC GGC ACT
CCC CTT GTA TGG
GTC TCT GAC ATC
406 P W E H E D Q E T G E G V K * 419 GAT GAG GAA TAG
Amino acid sequence of human amino acids)(SEQ ID N0:22).The seven GPCRx20 (419 predicted transmembrane domaines are underlined.
MLAAAFADSNSSSMNVSFAHLHFAGGYLPSDSQDWRTITPALLVAVCLVGFVGNLCVIGILLHNAWKGKPS
MIHSlILNL
SLADLSLLLFSAPIRATAYSKSVWDLGWFVCKSSDWFIHTCMAAKSLTIVWAKVCFMYASDPAKQVSIHN
YTIWSVLVA
IWTVASLLPLPEWFFSTIRHHEGVEMCLVDVPAVAEEFMSMFGKLYPLLAFGLPLFFASFYFWRAYDQCKKRGTKTQNL
R
NQTRSKQVTVMLLSIAIISALLWLPEWVAWLWVWHLKAAGPAPPQGFIALSQVLMFSISSANPLIFLVMSE
EFREGLKGV
WKWMITKKPPTVSESQETPAGNSEGLPDKVPSPESPASTPEKEKPSSPSSGKGKTEKAEIPILPDVEQFWHERDTVPSV
Q
DNDPIPWEHEDQETGEGVK
At the amino acid sequence the 20s identical the level, human to GPCRx20 is mouse galanin 2 receptor.
Claims (17)
1. A G-protein coupled receptor having an amino acid sequence which presents more than 75% sequence identity with the sequence SEQ ID NO. 1.
2. The G-protein coupled receptor according to claim 1, having an amino acid sequence which presents more than 80% sequence identity with the sequence SEQ ID NO. 1.
3. The G-protein coupled receptor according to claim 1, having an amino acid sequence which presents more than 85% sequence identity with the sequence SEQ ID NO. 1.
4. The G-protein coupled receptor according to claim 1, having an amino acid sequence which presents more than 90% sequence identity with the sequence SEQ ID NO. 1.
5. The G-protein coupled receptor according to claim 1, having an amino acid sequence which presents more than 95% sequence identity with the sequence SEA ID NO. 1.
6. The G-protein coupled receptor having the amino acid sequence SEQ ID NO. 1 or a specific active portion thereof.
7. A polynucleotide encoding any of the amino acid sequences of the G-protein coupled receptor according to any of the preceding claims 1 to 6.
8. An agonist, reverse agonist, antagonist or inhibitor of the receptor or the polynucleotide according to any of the preceding claims 1 to 7.
9. A vector comprising the polynucleotide according to the claim 7.
10. A cell transformed by the vector according to the claim 9.
11. A non-human mammal comprising a partial or total deletion of the polynucleotide according to the claim 8 encoding the receptor according to any of the preceding claims 1 to 6, preferably an non-human mammal comprising an homologous recombination "knock-out" of said polynucleotide or a transgenic non-human mammal overexpressing above natural level said polynucleotide.
12. A method for the screening (detection and possibly recovering) of compounds or natural extract which are known or not known to be agonists, antagonists or inhibitors to the receptor according to any of the preceding claims 1 to 6, said method comprising:
- contacting a cell or cell extract from the cell transfected with a vector according to the claim 9, - possibly isolating a membrane fraction from the cell extract or the complete cell with a compound binding to said receptor under conditions permitting binding of said compound or molecules present in said natural extract to said receptor, possibly by the activation of a functional response, and - detecting the presence of any such compound or molecules by means of a bioassay (preferably a modification in the production of a second messenger or an increase in the receptor activity) in the presence of the other known compound working as an agonist, reverse agonist, antagonist or inhibitor to the receptor and thereby recovering and determining whether said unknown compound or molecule(s) is (are) able to work as an agonist, antagonist or inhibitor of the compound to its receptor.
- contacting a cell or cell extract from the cell transfected with a vector according to the claim 9, - possibly isolating a membrane fraction from the cell extract or the complete cell with a compound binding to said receptor under conditions permitting binding of said compound or molecules present in said natural extract to said receptor, possibly by the activation of a functional response, and - detecting the presence of any such compound or molecules by means of a bioassay (preferably a modification in the production of a second messenger or an increase in the receptor activity) in the presence of the other known compound working as an agonist, reverse agonist, antagonist or inhibitor to the receptor and thereby recovering and determining whether said unknown compound or molecule(s) is (are) able to work as an agonist, antagonist or inhibitor of the compound to its receptor.
13. An unknown compound or molecule(s), identified by the screening method according to the claim 12.
14. A pharmaceutical composition comprising an adequate pharmaceutical carrier and a sufficient amount of the compound or molecules according to the claim 8 or 13.
15. Use of the pharmaceutical composition according to the claim 14, for the manufacture of a medicament in the prevention and/or the treatment of a disease selected from the group consisting of viral infections or diseases induced by various viruses or bacteria, the treatment of disturbances of cell migration, diseases or perturbations of the immune system, including cancer, development of tumours and tumour metastasis, inflammatory and neo-plastic processes, bacterial and fungal infections, for wound and bone healing and dysfunction of regulatory growth functions, pains, diabetes, obesity, anorexia, bulimia, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, restenosis, atherosclerosis, diseases characterised by excessive smooth muscle cell proliferation, aneurysms, wound healing, diseases characterised by loss of smooth muscle cells or reduced smooth muscle cell proliferation, stroke, ischemia, ulcers, allergies, benign prostatic hypertrophy, migraine, vomiting, psychotic and neurological disorders, including anxiety, schizophrenia, maniac depression, depression, delirium, dementia and severe mental retardation, degenerative diseases, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, and dyskinasias, such as Huntington's disease or Gilles de la Tourett's syndrome and other related diseases.
16. Use of the pharmaceutical composition according to the claim 14, for the manufacture of a medicament in the prevention and/or the treatment of blood circulating affections, including acute heart failure, hypotension, hypertension or myocardial infarction.
17. Diagnostic kit comprising all the media and means for detecting the receptor and nucleotide sequence encoding it or an activity of said receptor and nucleotide sequence encoding it according to any of the preceding claims 1 to 8.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21291300P | 2000-06-20 | 2000-06-20 | |
US60/212,913 | 2000-06-20 | ||
US21749400P | 2000-07-11 | 2000-07-11 | |
US60/217,494 | 2000-07-11 | ||
EP01870015.3 | 2001-01-26 | ||
EP01870015 | 2001-01-26 | ||
EP01870024 | 2001-02-12 | ||
EP01870024.5 | 2001-02-12 | ||
PCT/BE2001/000104 WO2001098330A2 (en) | 2000-06-20 | 2001-06-20 | A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2413435A1 true CA2413435A1 (en) | 2001-12-27 |
Family
ID=56290152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002413435A Abandoned CA2413435A1 (en) | 2000-06-20 | 2001-06-20 | A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1297003A2 (en) |
JP (1) | JP2004500125A (en) |
AU (1) | AU2001265717A1 (en) |
CA (1) | CA2413435A1 (en) |
WO (1) | WO2001098330A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008258A2 (en) * | 2000-07-21 | 2002-01-31 | Millennium Pharmaceuticals, Inc. | 65494, a human g-protein-coupled receptor family member and uses thereof |
GB2367297A (en) * | 2000-07-07 | 2002-04-03 | Smithkline Beecham Corp | AXOR95 polypeptides and polynucleotides |
MXPA03007270A (en) * | 2001-02-14 | 2003-12-04 | Amgen Inc | G-protein coupled receptor molecules and uses thereof. |
DE60228559D1 (en) * | 2001-04-25 | 2008-10-09 | Astellas Pharma Inc | GUANOSINTRIPHOSPHATE BINDING PROTEIN-COUPLED RECEPTOR PLACE 6002312 AND ITS GENE AND ITS PRODUCTION AND USE |
JPWO2003027142A1 (en) * | 2001-09-21 | 2005-01-06 | 山之内製薬株式会社 | Novel G protein coupled receptor |
WO2003046147A2 (en) * | 2001-11-26 | 2003-06-05 | Bristol-Myers Squibb Company | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof |
EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
DE10225443A1 (en) * | 2002-06-08 | 2003-12-18 | Aventis Pharma Gmbh | Binding assay for identifying compounds that react with the mas-like-1 receptor, useful for treating cardiovascular disease, including activators and inhibitors |
WO2004042402A2 (en) * | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
EP1565748A2 (en) * | 2002-11-22 | 2005-08-24 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
CA2526847C (en) | 2003-06-20 | 2011-01-25 | Ambit Biosciences Corporation | Assay and kits for detecting protein binding |
WO2008063321A2 (en) | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9704836D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
WO2001016159A1 (en) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, theant |
CN1379816A (en) * | 1999-09-16 | 2002-11-13 | 索尔瓦药物有限公司 | Human G-protein coupled receptor |
CA2388865A1 (en) * | 1999-11-16 | 2001-05-25 | Pharmacia & Upjohn Company | Novel g protein-coupled receptors |
NZ531722A (en) * | 1999-11-17 | 2006-06-30 | Arena Pharm Inc | Endogenous and non-endogenous versions of human G protein-coupled receptors |
AU2230401A (en) * | 1999-12-28 | 2001-07-09 | Helix Research Institute | Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and use of the same |
EP1242454A2 (en) * | 1999-12-28 | 2002-09-25 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
-
2001
- 2001-06-20 EP EP01942923A patent/EP1297003A2/en not_active Withdrawn
- 2001-06-20 JP JP2002504285A patent/JP2004500125A/en active Pending
- 2001-06-20 WO PCT/BE2001/000104 patent/WO2001098330A2/en not_active Application Discontinuation
- 2001-06-20 CA CA002413435A patent/CA2413435A1/en not_active Abandoned
- 2001-06-20 AU AU2001265717A patent/AU2001265717A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001098330A3 (en) | 2002-05-02 |
AU2001265717A1 (en) | 2002-01-02 |
WO2001098330A2 (en) | 2001-12-27 |
JP2004500125A (en) | 2004-01-08 |
EP1297003A2 (en) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kolakowski Jr et al. | Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3 | |
JP4790836B2 (en) | Parathyroid hormone receptor and DNA encoding it | |
US5545549A (en) | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof | |
JPH10179178A (en) | Human 7-transmembrane type receptor | |
PL182324B1 (en) | Protocadherine proteins and their applications | |
KR20010033601A (en) | Polypeptide, their production and use | |
CA2413435A1 (en) | A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists | |
CA2199470A1 (en) | Allelic variation of the serotonin 5ht2c receptor | |
EP0614487A1 (en) | Dna encoding a glycine transporter and uses thereof | |
JP2000083669A (en) | Human splicing variant cxcr4b of cxcr4 kemokine receptor | |
JPH1128093A (en) | New cdna clone hdpbi 30 encoding human 7-transmembrane receptor | |
US5591602A (en) | Nucleic acid encoding opioid receptor | |
WO1995012670A9 (en) | Opioid receptor: compositions and methods | |
JPH119289A (en) | Novel 7tm receptor | |
JPH10179180A (en) | Mouse genom clone of cc-ckr5 receptor | |
AU748167B2 (en) | Novel nucleic acid and polypeptide | |
JPH10243788A (en) | Complementary-dna clone hnfjd15 that encodes novel human 7-transmembrane receptor | |
AU753400C (en) | Orphan receptors | |
JP2000078994A (en) | Complementary dna clone hnfdy20 encoding new 7- transmembrane receptor | |
JPH10210993A (en) | Cdna clone he8ch90 coding new 7-transmembrane receptor | |
US6998255B1 (en) | Human G-protein coupled receptor | |
WO2002044212A2 (en) | Human g-protein coupled receptor and uses thereof | |
US20030139589A1 (en) | G protein coupled receptor A4 | |
Jung | Discovery and characterization of three genes encoding G protein-coupled receptors | |
JP2001309792A (en) | Method for screening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |